A Phase I/II Study of CX-4945 in Combination With Gemcitabine and Cisplatin in the Frontline Treatment of Patients With Cholangiocarcinoma

Trial Profile

A Phase I/II Study of CX-4945 in Combination With Gemcitabine and Cisplatin in the Frontline Treatment of Patients With Cholangiocarcinoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Jan 2017

At a glance

  • Drugs Silmitasertib (Primary) ; Cisplatin; Gemcitabine
  • Indications Cholangiocarcinoma
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Senhwa Biosciences
  • Most Recent Events

    • 21 Jan 2017 Results (n=19) presented at the 2017 Gastrointestinal Cancers Symposium
    • 06 Dec 2016 According to Senhwa Biosciences media release, results from this trial will be presented at the 2017 Gastrointestinal Cancers Symposium, by the American Society for Clinical Oncology (ASCO).
    • 22 Oct 2015 According to a Senhwa Biosciences media relese, the company has received permission from the Taiwan Food and Drug Administration to conduct this trial in Taiwan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top